Table 1. Clinical data summary.
| Characteristic | AC (n=103) | SQCLC (n=183) | SCLC (n=37) |
|---|---|---|---|
| Gender, n (%) | |||
| Male | 59 (57.3) | 154 (84.2) | 27 (73.0) |
| Female | 44 (42.7) | 29 (15.8) | 10 (27.0) |
| Median age [range] (years) | 67 [34–85] | 66 [42–83] | 65 [50–77] |
| Tumor grade, n (%) | |||
| G1–2 | 74 (73.8) | 140 (76.5) | 0 (0.0) |
| G3 | 27 (26.2) | 43 (23.5) | 37 (100.0) |
| Tumor stage, n (%) | |||
| T stage | |||
| T1–2 | 82 (80.0) | 131 (72.4) | 35 (89.7) |
| T3–4 | 20 (20.0) | 50 (27.6) | 2 (10.3) |
| N stage | |||
| N0 | 62 (63.3) | 99 (55.6) | 21 (75.0) |
| N1–3 | 36 (36.7) | 79 (44.4) | 7 (25.0) |
| Median survival time (months) | 40 | 30 | 58 |
| Median follow-up time [range] (months) | 23 [1–128] | 26 [1–196] | 34 [1–125] |
| Reported deaths (%) | 48 (46.7) | 131 (71.6) | 22 (59.5) |
AC, pulmonary adenocarcinoma; SQCLC, squamous cell lung cancer; SCLC, small cell lung cancer.